632 related articles for article (PubMed ID: 30396176)
1. Omalizumab in Chronic Urticaria: An Italian Survey.
Damiani G; Diani M; Conic RRZ; Colli L; Ferrucci S; Martina E; Offidani AM; Pigatto PDM
Int Arch Allergy Immunol; 2019; 178(1):45-49. PubMed ID: 30396176
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
3. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
6. Long-term management of chronic spontaneous urticaria with omalizumab.
Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
9. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Omalizumab in Elderly Patients with Chronic Urticaria: Is It a Safe Therapy?
Narváez-Fernández EJ; Entrala A; Nin-Valencia A; Mir-Ihara P; Losantos-García I; Domínguez-Ortega J; González-Fernández MÁ; Quirce S; Hernández-Cano N; Cabañas R; Caballero T
Int Arch Allergy Immunol; 2023; 184(10):1003-1009. PubMed ID: 37231812
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
Giménez-Arnau AM
Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
[TBL] [Abstract][Full Text] [Related]
13. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
14. Use of omalizumab in the treatment of chronic urticaria.
Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP
Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
[TBL] [Abstract][Full Text] [Related]
15. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
Giménez-Arnau AM; Toubi E; Marsland AM; Maurer M
J Eur Acad Dermatol Venereol; 2016 Jul; 30 Suppl 5():25-32. PubMed ID: 27286500
[TBL] [Abstract][Full Text] [Related]
16. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.
Chen Y; Yu M; Huang X; Tu P; Shi P; Maurer M; Zhao Z
World Allergy Organ J; 2021 Jan; 14(1):100501. PubMed ID: 33510832
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature.
Kasperska-Zajac A; Jarząb J; Żerdzińska A; Bąk K; Grzanka A
Int J Immunopathol Pharmacol; 2016 Jun; 29(2):320-8. PubMed ID: 26729404
[TBL] [Abstract][Full Text] [Related]
20. Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria.
Syrigos N; Grapsa D; Zande M; Tziotou M; Syrigou E
Int J Dermatol; 2018 Apr; 57(4):417-422. PubMed ID: 29399789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]